The decrement in circulating endothelial progenitor cells (EPCs) in type 2 diabetes is independent of the severity of the hypoadiponectemia

2011 ◽  
Vol 27 (2) ◽  
pp. 185-194 ◽  
Author(s):  
Mingfang Li ◽  
Jenny C. Y. Ho ◽  
Kevin W. H. Lai ◽  
Karen K. W. Au ◽  
Aimin Xu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Endothelial Progenitor ◽  
Circulating Endothelial Progenitor Cells

scholarly journals RELATION OF GROWTH-DIFFERENTIATION FACTOR-15 LEVELS AND NUMBER OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

2018 ◽  
Vol 2 (2) ◽  
pp. 15-15
Author(s):  
Alexander A. Kremzer ◽  
Ivan M. Fushtey ◽  
Alexander A. Berezin
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Endothelial Progenitor ◽  
Growth Differentiation Factor 15 ◽  
Differentiation Factor ◽  
Circulating Endothelial Progenitor Cells

RELATION OF GROWTH-DIFFERENTIATION FACTOR-15 LEVELS AND NUMBER OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Alogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients

2018 ◽  
Vol 127 (04) ◽  
pp. 215-219 ◽  
Author(s):  
Roberto Negro ◽  
Eupremio Greco ◽  
Giacomo Greco
Keyword(s):  
Type 2 Diabetes ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Extended Release ◽  
Endothelial Progenitor ◽  
Glucose Lowering ◽  
Circulating Endothelial Progenitor Cells ◽  
Glucose Lowering Effect ◽  
To Receive

Abstract Aim We investigated the effect of alogliptin and gliclazide on endothelial progenitor cells (EPCs) in type 2 diabetes. Methods Eighty patients with type 2 diabetes and HbA1c between 7.5% and 8.5% were randomized to receive either alogliptin (25 mg/daily) or gliclazide extended-release (30 mg/daily for HbA1c 7.5-8.0% and 60 mg/daily for HbA1c 8.0-8.5%) in combination with metformin for 4 months. At baseline and 4 months, clinical and laboratory parameters of EPCs were determined. Results After 4 months of treatment, alogliptin and gliclazide resulted in a similar significant reduction in HbA1c (%) (8.0±0.3 vs. 7.1±0.2, and 8.0±0.3 vs. 7.0±0.2, respectively; P<0.05) and a similar and significant increase in EPC count (cells/106 WBC) (CD45−CD133+KDR+ : 2.2±1.2 vs. 3.7±1.6, CD45−CD34+KDR+: 3.3±1.8 vs. 4.9±1.8; P<0.05 for alogliptin; CD45−CD133+KDR+: 2.3±1.3 vs. 3.6±1.5, CD45−CD34+KDR+: 3.1±1.3 vs. 4.6±1.7; P<0.05 for gliclazide). Conclusions Both alogliptin and gliclazide demonstrated a beneficial effect in increasing EPCs in poorly controlled type 2 diabetes. As alogliptin and gliclazide exhibit different mechanisms of action, the observed increase in EPCs seems to be due to their glucose-lowering effect.

Sign in / Sign up

Export Citation Format

Share Document